There are 621 papers on hepatic steatosis in aging research: 40 trials and 140 observational studies in people, 314 in animals, 13 in cells, 107 reviews. The newest story, Nov 16, 2026: “A protein helps control fat breakdown in mouse livers”.
Caloric restriction decreases hepatic steatosis in humans (combined analysis after surgical or dietary intervention) (-19.0 ± 17.3%).
“In a combined analysis, mean ± SD hepatic fat content significantly decreased after surgical or dietary intervention by 19.0 ± 17.3%, from 12.9 ± 11.4% fat content at baseline (range 2.7–38.9) to 10.8 ± 10.2% after intervention (2.5–32.5) (P = 0.0071) (Supplementary Fig. 1B).”
Human trialcombined analysis after surgical or dietary intervention7–9 daysn = 20
Caloric restriction showed no clear effect on hepatic steatosis in humans.
“At the end of the study, no significant changes were observed in patients’ liver steatosis grades either within or between the two groups (p > 0.05), although two patients in the CR diet group had a decreased steatosis grade and one patient in the control group had an increased steatosis grade.”
Caloric restriction protects against hepatic steatosis in obese rats after sleeve gastrectomy.
“CRD intake exerted the protective effects against hepatic steatosis and fibrosis, emerging as an effective adjunct to bariatric surgery for managing obesity-related MASLD.”
Animalsin obese rats after sleeve gastrectomyliver18 weeksmales
Caloric restriction increases hepatic steatosis in offspring of 50% calorically restricted obese fathers.
“HFCR-I offspring also developed altered glucose and lipid homeostasis by exhibiting impaired glucose tolerance & insulin sensitivity, dyslipidemia and steatosis.”
Animalsin offspring of 50% calorically restricted obese fathers
Caloric restriction decreases hepatic steatosis in rats.
“Such alterations were ameliorated by caloric restriction in combination with a mixed training protocol and/or food-intake inhibitor administration during a weight loss intervention period of 3 weeks”
Animalscombined with mixed training protocol and/or appetite suppressant in high-fat diet-induced obese ratsliver3-week weight loss intervention
GLP-1 receptor agonists decrease hepatic steatosis in humans.
“Clinical trials have consistently demonstrated coordinated improvements in glycaemic control, hepatic steatosis, body composition, insulin sensitivity, cardiovascular and renal outcomes, inflammatory activity, mitochondrial metabolism and energy expenditure”
GLP-1 receptor agonists decrease hepatic steatosis in humans.
“GLP-1 RAs (e.g., liraglutide and semaglutide) consistently demonstrate hepatic benefits, including reductions in hepatic steatosis, improvements in liver enzyme profiles, and attenuation of fibrosis progression.”
GLP-1 receptor agonists decrease hepatic steatosis in patients with NAFLD.
“GLP-1RAs are effective in improving the clinical, biochemical, and histological markers of hepatic steatosis, inflammation, and fibrosis in patients with NAFLD”
Metformin protects against hepatic steatosis in mice (aging-dependent steatosis; long-term treatment).
“reducing phospho-STAT3-miR-21 levels in C57/BL6 mice liver, by long-term treatment with metformin, protected mice from aging-dependent hepatic vesicular steatosis”
Tirzepatide is linked with lower hepatic steatosis in individuals with Alström syndrome (fat fraction 20% resolved in first case; 21% to 11% in second case).
“Hepatic steatosis, with a previous fat fraction of 20%, resolved as confirmed by magnetic resonance imaging (MRI).”
Humansin individuals with Alström syndromeliver9 to 18 monthsmalesn = 2
The Journal of clinical endocrinology and metabolism·
Tirzepatide decreases hepatic steatosis in humans.
“Furthermore, the dual-receptor agonist tirzepatide represents a major paradigm shift, leveraging dual-receptor synergy to provide superior weight loss, optimize adipose tissue function, and reduce hepatic steatosis.”
Tirzepatide decreases hepatic steatosis in HFD-fed female Brca1+/- mice.
“Treatment with the dual GLP1/GIP receptor agonist tirzepatide ameliorated systemic metabolic dysfunction and hepatic steatosis in HFD-fed female Brca1+/- mice.”
Nicotinamide riboside decreases hepatic steatosis in mice.
“NR-treated mice were protected against HFD-induced triacylglycerol accumulation in skeletal muscle and displayed lower triacylglycerol levels and steatosis degree in the liver”
Nicotinamide riboside decreases hepatic steatosis in HFD-induced NAFLD mice.
“In HFD-induced NAFLD mice model, NR displayed remarkable therapeutic effects on body weight gain, hepatic steatosis, steatohepatitis, insulin resistance, mitochondrial dysfunction, apoptosis and fibrosis”
Resveratrol decreases hepatic steatosis in humans (along with lifestyle modification in NAFLD patients) (P < .05).
“Resveratrol supplementation was associated with a significant reduction in liver enzyme alanine aminotransferase, inflammatory cytokines, nuclear factor κB activity, serum cytokeratin-18, and hepatic steatosis grade, as compared with placebo supplementation”
Human trialalong with lifestyle modification in NAFLD patientscapsule500-mg12 weeksn = 50
Intermittent calorie restriction decreases hepatic steatosis in humans (versus standard of care in patients with NAFLD) (absolute reduction -6.1% [95% CI -8.1 to -4.2] vs -3.6% with standard of care).
“The LCHF and 5:2 diets were both superior to SoC treatment in reducing steatosis”
Human trialversus standard of care in patients with NAFLD5:2 dietliver12 weeks
Digital lifestyle intervention decreases hepatic steatosis in humans (RR 1.816, 95% CI 1.102-2.992).
“patients receiving the intervention were significantly more likely to achieve a ≥10% reduction or normalization of controlled attenuation parameter (CAP) than those in the control group”
Yeast-free diet decreases hepatic steatosis in humans after 6 months compared with standard diet.
“While no difference was found in terms of fatty liver at 3 months in the pairwise comparisons between the diet groups, statistical significance was observed between the standard diet and both WFFD and YFD at 6 months.”
Human trialafter 6 months compared with standard diet6 monthsn = 243
Wheat flour-free diet decreases hepatic steatosis in humans after 6 months compared with standard diet.
“While no difference was found in terms of fatty liver at 3 months in the pairwise comparisons between the diet groups, statistical significance was observed between the standard diet and both WFFD and YFD at 6 months.”
Human trialafter 6 months compared with standard diet6 monthsn = 243
Hepatic steatosis is linked with major adverse liver events in humans (Mediation of the association between CKM stage and major adverse liver events) (41.1% mediated).
“For MALEs, hepatic steatosis mediated 41.1% of the association with CKM stage.”
HumansMediation of the association between CKM stage and major adverse liver events
Hepatic steatosis is linked with metabolic syndrome in humans (mediating DI-GM-MetS association) (accounted for approximately 65% (indirect effect: -0.0263; P < 0.01)).
“In mediation analysis, hepatic steatosis accounted for approximately 65% of the DI‐GM-MetS association (indirect effect: -0.0263; P < 0.01)”
Autophagy is required for hepatic steatosis in rats (protective effects of caloric restriction and resveratrol against HFD-induced steatosis).
“the SIRT1-autophagy pathway and decreased ER stress are universally required for the protective effects of moderate caloric restriction (30%) and resveratrol”
Animalsprotective effects of caloric restriction and resveratrol against HFD-induced steatosisliver30% caloric restriction; 200 mg/kg bw resveratrol18 weeksmales
Hepatic steatosis is associated with major adverse cardiovascular events in humans (new-onset atrial fibrillation; propensity score-matched analysis) (1.19-fold higher incidence; 72.2 vs.59.8 per 1,000 person-years; adjusted hazard ratio increased by 9%).
“the HS group exhibited a 1.19-fold higher incidence of MACE compared to the non-HS group”
Hepatic steatosis is associated with major adverse cardiovascular events in humans (SHR 1.21; 95% CI 1.15-1.29).
“FLI-defined hepatic steatosis was associated with incident diabetes (SHR 1.67; 95% CI 1.59-1.76; P < 0.001) and composite MACE (SHR 1.21; 95% CI 1.15-1.29; P < 0.001).”
HumansWithout diabetes at baseline; hepatic steatosis defined by FLI ≥ 60; multivariable adjustmentn = 142,518
Hepatic steatosis is associated with ischemic stroke in humans (new-onset atrial fibrillation; propensity score-matched analysis) (adjusted hazard ratio increased by 8%).
“PSM-adjusted hazard ratios (HRs) for MACE, HF, and ischemic stroke increased by 9%, 12%, and 8%, respectively, in the HS group”
Hepatic steatosis is associated with heart failure hospitalization in humans (new-onset atrial fibrillation; propensity score-matched analysis) (adjusted hazard ratio increased by 12%).
“PSM-adjusted hazard ratios (HRs) for MACE, HF, and ischemic stroke increased by 9%, 12%, and 8%, respectively, in the HS group”
Hepatic steatosis is associated with log-transformed lipoprotein(a) concentrations in humans (hepatic steatosis versus no hepatic steatosis) (9% lower (95% CI: 5% to 13%)).
“men with HS had a 9% (95% confidence interval [CI]: 5% to 13%; p<0.001) lower log-transformed Lp(a) concentrations than those without HS”
Humanshepatic steatosis versus no hepatic steatosisserummales
Hepatic steatosis is associated with prevalent carotid plaque in humans (Multivariable-adjusted association) (OR 1.167, 95% CI 1.111–1.226).
“Ultrasound-detected hepatic steatosis was associated with higher odds of prevalent carotid plaque after multivariable adjustment (OR 1.167, 95% CI 1.111–1.226).”
Experiments in mouse models of fatty liver disease showed that raising the protein’s levels protected against fat buildup and liver injury.Experiments in mouse models of fatty liver disease showed that raising the protein’s levels protected against fat buildup and liver injury.